Combination Chemotherapy with Mitomycin C, Vinorelbine, and Cisplatin (MVrP) in Patients with Advanced Non-Small Cell Lung Cancer.
- Author:
Hun Gu KIM
1
;
Gyeong Won LEE
;
Dae Hwan LEE
;
In Gyu HWANG
;
Ki Shik SHIM
;
Won Sup LEE
;
Jong Deog LEE
;
Joung Soon JANG
;
Young Sil HWANG
;
Jong Seok LEE
Author Information
1. Department of Internal Medicine, College of Medicine, Gyeongsang National University, Jinju, Korea. jonglee@nongae.gsnu.ac.kr
- Publication Type:Original Article
- Keywords:
Non-small cell lung cancer;
Combination chemotherapy;
Mitomycin C;
Vinorelbine;
Cisplatin
- MeSH:
Carcinoma, Non-Small-Cell Lung*;
Cisplatin*;
Drug Therapy, Combination*;
Humans;
Mitomycin*
- From:Cancer Research and Treatment
2001;33(5):377-384
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: A phase II study was conducted in patients with advanced non-small cell lung cancer (NSCLC) in order to evaluate the efficacy and toxicity of the combination chemotherapy regimen of mitomycin C, vinorelbine, and cisplatin (MVrP). MATERIALS AND METHODS: Between June 1996 and December 2000, fifty-nine patients with unresectable stage IIIB to IV, pathologically documented NSCLC were enrolled in this study. One cycle consisted of mitomycin C 10 mg/m2 i.v. day 1, vinorelbine 30 mg/m2 i.v. days 1 & 15, and cisplatin 80 mg/m2 i.v day 1 and the next cycle consisted of vinorelbine 30 mg/m2 i.v. days 29 & 43, and cisplatin 80 mg/m2 i.v day 29. Each cycle was alternated and treatments were repeated every 8 weeks. RESULTS: We were able to evaluate fifty-three of 59 patients. Objective responses were seen in 22 (41.5%) patients (CR 0%, PR 41.5%). The median duration of response was 13.7 weeks and the median time to progression was 17.7 weeks. The median overall survival was 45.6 weeks. There was a significantly longer survival seen in responders (p=0.041). The toxicities of this regimen were acceptable without treatment related toxic death. CONCLUSION: This study suggests that a combination regimen of mitomycin C, vinorelbine, and cisplatin is relatively effective and well tolerated for the treatment of advanced NSCLC.
